Melanoma cells present a MAGE-3 epitope to CD4+ cytotoxic T cells in association with histocompatibility leukocyte antigen DR11

Journal of Experimental Medicine

Volumn 189, Issue 5, 1999, Pages 871-876

  Manici, Simona ^a   Sturniolo, Tiziana ^b   Imro, Maria Adele ^a   Hammer, Juergen ^c   Sinigaglia, Francesco ^b   Noppen, Christoph ^d   Spagnoli, Giulio ^d   Mazzi, Benedetta ^a   Bellone, Matteo ^a   Dellabona, Paolo ^a   Protti, Maria Pia ^a  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b ROCHE MILANO RICERCHE   (Italy)

^c HOFFMANN LA ROCHE INC   (United States)

^d UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

CD4+ epitopes; MAGE 3; Melanoma; Tumor vaccines adoptive immunotherapy

Indexed keywords

HISTOCOMPATIBILITY ANTIGEN; HLA DR ANTIGEN; LEUKOCYTE ANTIGEN;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CANCER CELL; CELL PROLIFERATION; CYTOTOXIC T LYMPHOCYTE; EFFECTOR CELL; EPITOPE MAPPING; HELPER CELL; HUMAN; HUMAN CELL; MELANOMA; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; TISSUE SPECIFICITY; TUMOR IMMUNITY; VACCINATION;

AMINO ACID SEQUENCE; ANTIGEN PRESENTATION; ANTIGENS, NEOPLASM; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CYTOTOXICITY, IMMUNOLOGIC; DRUG DESIGN; EPITOPES; FORECASTING; HLA-DR ANTIGENS; HUMANS; LYMPHOCYTE ACTIVATION; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; PEPTIDE FRAGMENTS; PROTEIN BINDING; PROTEIN PROCESSING, POST-TRANSLATIONAL; SOFTWARE; T-LYMPHOCYTE SUBSETS;

EID: 0033103192     PISSN: 00221007     EISSN: None     Source Type: Journal    
DOI: 10.1084/jem.189.5.871     Document Type: Article

References (33)

1. Greenberg, P.D. 1991. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49:281-355.
2. Chen, P., and H. Aanathaswamy. 1993. Rejection of K1735 murine melanoma in syngeneic hosts requires expression of MHC class I antigens and either class II antigens or IL-2. J. Immunol. 151:244-255.
3. Mandelboim, O., E. Vadai, M. Fridkin, A. Katz-Hillel, M. Feldman, G. Berke, and L. Eisenbach. 1995. Regression of established murine carcinoma metastases following vaccination with tumor-associated antigen peptides. Nat. Med. 1:1179-1183.
4. Mayordomo, J.I., T. Zorina, W.J. Storkus, L. Zitvogel, C. Celluzzi, L.D. Falo, C.J.M. Melief, S.T. Ildstad, W.M. Kast, A.B. Deleo, and M.T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumor peptides elicit protective and therapeutic antitumor immunity. Nat. Med. 1:1297-1302.
5. Bellone, M., G. Iezzi, A. Martin-Fontecha, L. Rivolta, A.A. Manfredi, M.P. Protti, M. Freschi, P. Dellabona, G. Casorati, and C. Rugarli. 1997. Rejection of a non-immunogenic melanoma by vaccination with natural melanoma peptides on engineered APC. J. Immunol. 158:783-789.
6. Ostrand-Rosemberg, S., A. Thakur, and V. Clements. 1990. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol. 144:4068-4071.
7. James, R., S. Edwards, K. Hui, P. Bassett, and F. Grosveld. 1991. The effect of class II gene transfection on the tumorigenicity of the H-2K negative mouse leukemia cell line K36.16. Immunology. 72:213-218.
8. Ossendorp, F., E. Mengedé, M. Camps, R. Filius, and C.J.M. Melief. 1998. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187:693-702.
9. + tumor-infiltrating lymphocytes in human solid tumors. Immunol. Res. 14:119-131.
10. + cytotoxic T-cell clones directed to autologous human melanoma identified by cytokine profiles. Int. J. Cancer. 57:56-62.
11. Sahin, U., O. Tureci, and M. Pfreundschuh. 1997. Serological identification of human tumor antigens. Curr. Opin. Immunol. 9:709-716.
12. + T cells specifically recognize a shared melanoma-associated antigen encoded by the tyrosinase gene. Proc. Natl. Acad. Sci. USA. 91:9461-9465.
13. + T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J. Immunol. 157:4079-4086.
14. + T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes. J. Exp. Med. 183:1965-1971.
15. Van den Eynde, B.J., and P. van der Bruggen. 1997. T cell defined tumor antigens. Immunol. Today. 9:684-693.
16. Kocher, T., E. Schultz-Tjater, F. Gudat, C. Schaefer, G. Casorati, A. Juretic, T. Willimann, F. Harder, M. Heberer, and G. Spagnoli. 1995. Identification and intracellular location of MAGE-3 gene product. Cancer Res. 55:2236-2239.
17. Nuchtern, J.G., W.E. Biddison, and R.D. Klausner. 1990. Class II MHC molecules can use the endogenous pathway of antigen presentation. Nature. 343:74-76.
18. Chen, B.P., A. Madrigal, and P. Parham. 1990. Cytotoxic T cell recognition of an endogenous class I HLA peptide presented by a class II HLA molecule. J. Exp. Med. 172:779-788.
19. Chicz, R.M., R.G. Urban, J.C. Gorga, D.A. Vignali, W.S. Lane, and J.L. Strominger. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27-47.
20. Halder, T., G. Pawelec, A.F. Kirkin, J. Zeuthen, H.E. Meyer, L. Kun, and H. Kalbacher. 1997. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. Cancer Res. 57:3228-3244.
21. Hammer, J., T. Sturniolo, and F. Sinigaglia. 1997. HLA class II binding specificity and autoimmunity. Adv. Immunol. 66: 67-100.
22. Hammer, J., E. Bono, F. Gallazzi, C. Belunis, Z.A. Nagy, and F. Sinigaglia. 1994. Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning. J. Exp. Med. 180:2353-2358.
23. Raddrizzani, L., T. Sturniolo, J. Guenot, E. Bono, F. Gallazzi, Z.A. Nagy, F. Sinigaglia, and J. Hammer. 1997. Different modes of peptide interaction enable HLA-DQ and HLA-DR molecules to bind diverse peptide repertoires. J. Immunol. 159:703-711.
24. Cammarota, G., A. Scheirle, B. Takacs, D.M. Doran, R. Knorr, W. Bannwarth, J. Guardiola, and F. Sinigaglia. 1992. Identification of a CD4 binding site on the β2 domain of HLA-DR molecules. Nature. 356:799-801.
25. Sinigaglia, F., P. Romagnoli, M. Guttinger, B. Takacs, and J.R.L. Pink. 1992. Selection of T-cell epitopes and vaccine engineering. Methods Enzymol. 203:370-386.
26. Hammer, J., F. Gallazzi, E. Bono, R.W. Karr, J. Guenot, P. Valsasnini, Z.A. Nagy, and F. Sinigaglia. 1995. Peptide binding specificity of HLA-DR4 molecules: correlation with rheumatoid arthritis association. J. Exp. Med. 181:1847-1855.
27. Roche, P.A., and P. Cresswell. 1990. High-affinity binding of an influenza hemagglutinin-derived peptide to purified HLA-DR. J. Immunol. 144:1849-1856.
28. + cell lines from myasthenia gravis patients. J. Immunol. 144: 1711-1720.
29. + cytotoxic T lymphocytes in vitro. Hum. Gene Ther. 9:1335-1344.
30. Protti, M.P., M.A. Imro, A.A. Manfredi, G. Consogno, S. Heltai, C. Arcelloni, M. Bellone, P. Dellabona, G. Casorati, and C. Rugarli. 1996. Particulate naturally processed peptides prime a cytotoxic response against human melanoma in vitro. Cancer Res. 56:1210-1213.
31. Rosenberg, S.A., J.C. Yang, D.J. Schwartzentruber, P. Hwu, F.M. Marincola, S.L. Topalian, N.P. Restifo, M.E. Dudley, S.L. Schwarz, P.J. Spiess, et al. 1998. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med. 4:321-327.
32. Thomas, W.D., and P. Hersey. 1998. CD4 T cells kill melanoma cells by mechanisms that are independent of FAS (CD95). Int. J. Cancer. 75:384-390.
33. + T lymphocytes against human melanoma. Evidence for a shared melanoma antigen presented by HLA-DR15. J. Immunol. 154:772-779.